Features | Partner Sites | Information | LinkXpress
Sign In
VIEWORKS
Advantech Europe
Schiller

Codeine Following Tonsillectomy Contraindicated in Children

By HospiMedica International staff writers
Posted on 07 Mar 2013
A new safety review shows that products that contain codeine should not be used for pain relief following tonsillectomy or adenoidectomy in children, due to a possible risk of serious adverse events.

The warning, issued by the US Food and Drug Administration (FDA; Silver Spring, MD, USA), is based on reports of three deaths and one life-threatening case of respiratory depression published in the medical literature following the use of codeine in children with obstructive sleep apnea (OSA) who underwent tonsillectomy or adenoidectomy. The children were determined to be ultra-rapid metabolizers, genetically susceptible to converting normal doses of codeine into dangerous levels of morphine in the body.

Following the reports, a review of the FDA's Adverse Event Reporting System from 1969 to May 1, 2012, and a physician survey conducted by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS; Alexandria, VA, USA) uncovered a total of 12 deaths and three overdoses associated with codeine use in patients ranging in age from 21 months to 9 years. Eight of the cases involved codeine use after adenotonsillectomy, and three involved a respiratory tract infection. The codeine doses were appropriate in most cases.

“Since these children already had underlying breathing problems, they may have been particularly sensitive to the breathing difficulties that can result when codeine is converted in the body to high levels of morphine,” concluded the FDA advisory. “However, [the new] contraindication applies to all children undergoing tonsillectomy and/or adenoidectomy because it is not easy to determine which children might be ultra-rapid metabolizers of codeine.”

A boxed warning regarding the contraindication will be added to the labels of all codeine-containing products in the United States. The contraindication to codeine use does not apply to other types of pain management in children, although the FDA recommends that codeine should only be used if the benefits are anticipated to outweigh the risks.

Codeine (3-methylmorphine), a natural isomer of methylated morphine, is an opiate used for its analgesic, antitussive, antidiarrheal, antihypertensive, antianxiety, sedative, and hypnotic properties. It is used to suppress premature labor contractions, myocardial infarction (MI), cough suppression, as well as many other uses. Common adverse effects associated with the use of codeine include drowsiness, constipation, euphoria, itching, nausea, vomiting, and others. Rare adverse effects include anaphylaxis, seizure, and respiratory depression.

Related Links:

US Food and Drug Administration
American Academy of Otolaryngology-Head and Neck Surgery



Channels

Surgical Techniques

view channel
Image: The Percuvance Percutaneous Surgical System (Photo courtesy of Teleflex).

New Laparoscopic System Makes Trocar Use Redundant

A novel percutaneous surgical system does not require introductory trocars, thus leaving only a tiny mark on the patient’s skin following the procedure. The Percuvance Percutaneous Surgical System is... Read more

Women's Health

view channel

Women Undergoing Heart Attack Delay Hospital Arrival

Women suffering a heart attack wait much longer than men to call emergency medical services and face significantly longer delays getting to a hospital, according to a new study. Researchers at the University of Bologna (Italy) examined records of 7,457 European patients enrolled from 2010 to 2014 in an international... Read more

Health IT

view channel
Image: ResolutionMD across multiple devices (Photo courtesy of Calgary Scientific).

Healthcare Communication Platform Offers Seamless Image Access

Novel diagnostic medical imaging software offers better access to health information, supports increased teamwork, and enhances communication among practitioners and patients. ResolutionMD enables doctors... Read more

Business

view channel

New Hepatitis C Drugs Entail Economic Burden

The cost of treating people infected with the Hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous strain on the US healthcare system. Researchers at The University of Texas MD Anderson Cancer Center (Houston, TX, USA) conducted a cost-effectiveness analysis using a microsimulation... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.